Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.Antimicrobial agents and chemotherapy · 2004
   Trial
2. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.Antimicrobial agents and chemotherapy · 2004
   Trial
3. Paediatric Rheumatology Fails to Meet Current Benchmarks, a Call for Health Equity for Children Living with Juvenile Idiopathic Arthritis, Using Digital Health Technologies.Current rheumatology reports · 2024
   Review
4. Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.Biopharmaceutics & drug disposition · 2015
   Article
5. Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews.Paediatric drugs · 2011
   Article
6. Safety and transparency of pediatric drug trials.Archives of pediatrics & adolescent medicine · 2009
   Article
7. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil.European journal of clinical pharmacology · 2008
   Article
8. Safety monitoring of drugs receiving pediatric marketing exclusivity.Pediatrics · 2008
   Article
9. Documentation of pediatric drug safety in manufacturers' product monographs: a cross-sectional evaluation of the canadian compendium of pharmaceuticals and specialities.Paediatric drugs · 2008
   Article
10. Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring.Pharmaceutical research · 2003
    Article
11. Determinants for drug prescribing to children below the minimum licensed age.European journal of clinical pharmacology · 2003
    Article
12. Pharmacokinetic considerations in the treatment of childhood epilepsy.Paediatric drugs · 2003
    Review
13. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.Clinical pharmacokinetics · 2002
    Review
14. Clinical pharmacokinetics of sedatives in neonates.Clinical pharmacokinetics · 1996
    Review
15. Bayesian forecasting in paediatric populations.Clinical pharmacokinetics · 1996
    Review
16. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats.British journal of pharmacology · 1995
    Article
17. Paediatric labelling requirements. Implications for pharmacokinetic studies.Clinical pharmacokinetics · 1994
    Review
18. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.Clinical pharmacokinetics · 1992
    Review
19. Common errors of drug administration in infants: causes and avoidance.Paediatric drugs
    Review

Corrections and comments

• Comment on
  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.1992

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as